Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
Omalizumab and the risk of malignancy: Results from a pooled analysis
HTML
Details
Locations
Year:
2012
Type:
article
Source:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2012.01.033
Authors:
William Busse,
Roland Buhl,
Carlos Fernandez Vidaurre,
Martin Blogg,
Jin Zhu,
Mark D. Eisner,
Janice Canvin
show all 7
Institutions:
University of Wisconsin–Madison,
University of Wisconsin Health,
Johannes Gutenberg University Mainz,
University Medical Center of the Johannes Gutenberg University Mainz,
Novartis (United States),
Genentech
show all 6
Language:
English
Topic:
Pharmacovigilance and Adverse Drug Reactions
Subfield:
Toxicology
Field:
Pharmacology, Toxicology and Pharmaceutics
Domain:
Life Sciences
Keywords:
omalizumab,
cancer risk,
anti-IgE therapy,
drug safety,
pooled clinical trial data,
rate ratios
show all 6
SDG:
Good health and well-being
Open Access status:
closed
Funders:
Novartis,
Genentech
OpenAlex ID:
W1988223366
FWCI:
13.51
Cites:
62
Cited by:
178
Related to:
10